Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA012644-25
Application #
2086081
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1997-12-31
Budget Start
1996-01-01
Budget End
1996-12-31
Support Year
25
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Kansas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527

Showing the most recent 10 out of 266 publications